Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas
Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas
复制标题
DOI：
10.1007/s12020-018-1702-5
复制
发表时间：
2018-11-01
期刊：
影响因子：
3.7
通讯作者：
Wu, Zhe Bao
中科院分区：
文献类型：
--
作者：
Huang, Hai Yan;Zhai, Weiwei;Wu, Zhe Bao
很少有研究专门关注卡麦角林对溴隐亭耐药的侵袭性巨大泌乳素瘤（IGPs）的作用。本研究旨在评估卡麦角林是否可以作为一种有效的治疗溴隐亭耐药IGPs.MethodsThis回顾性研究包括15例溴隐亭耐药IGPs谁在我们的部门在2007-2015年期间接受治疗。所有15例患者均接受卡麦角林给药，剂量根据每例患者的催乳素反应进行调整。结果评估的参数包括催乳素水平，垂体功能，肿瘤大小，临床症状的改善，视野缺损，药物耐受性，和疾病reproduction.ResultsCabergoline是有效的治疗患者的溴隐亭耐药的IGPs所代表的12/15例患者的催乳素水平的正常化; 4/5例垂体功能减退症患者的垂体功能得到改善或正常化; 14/15例患者的肿瘤尺寸显着缩小; 11/15例患者的临床症状得到缓解。所有15例患者对卡麦角林均表现出良好的耐受性。此外，在平均随访期为63.47（范围30-145）months.ConclusionsData的回顾性研究表明，卡麦角林是一个很好的选择溴隐亭耐药的IGPs患者的治疗过程中没有观察到复发。
PurposeFew studies have specifically focused on the effect of cabergoline on invasive giant prolactinomas (IGPs) resistant to bromocriptine. This study aims to evaluate whether cabergoline could be used as an effective therapy for patients with bromocriptine-resistant IGPs.MethodsThis retrospective study included 15 patients with bromocriptine-resistant IGPs who received treatment at our department during 2007-2015. Cabergoline was administered in all 15 patients, with the dose adjusted depending on the prolactin response of each patient. Parameters for outcome assessment included prolactin level, pituitary function, tumor size, improvement of the clinical symptoms, visual field defects, drug tolerance, and disease recurrence.ResultsCabergoline was effective for the treatment of the patients with bromocriptine -resistant IGPs as represented by normalization of the prolactin level in 12/15 patients; improvement or normalization of the pituitary function in 4/5 patients with hypopituitarism; significant reduction in tumor size in 14/15 patients; and relief of the clinical symptoms in 11/15 patients. All 15 patients showed good tolerance to cabergoline. In addition, no recurrence was observed during the mean follow-up period of 63.47 (range 30-145) months.ConclusionsData of this retrospective study demonstrate that cabergoline is an excellent option for the treatment of patients with bromocriptine-resistant IGPs.